2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Review slidesets and expert analyses of key data from the 2022 Clinical Oncology Annual Scientific Meeting!

Hematologic Malignancies

Capsule Summary Slidesets

At a median follow-up of 2.3 years, asciminib continues to show deeper and more durable responses with more favorable safety compared with bosutinib among patients with CML-CP previously treated with ≥2 TKIs.

Released: June 9, 2022

Comutational profiles and survival benefits from enasidenib appear to differ based on presence of the IDH2 R140 or IDH2 R172 mutation, warranting additional research to clarify the influence of the various mutations on treatment outcomes.

Released: June 13, 2022

In this retrospective analysis of CIBMTR-collected blood samples, NGS-MRD detection of NPM1 mutations and/or FLT3-ITD was associated with significant prognostic value for relapse and survival in patients with AML in first remission prior to allogeneic HCT.

Released: June 17, 2022

Patients with newly diagnosed FLT3-mutated AML demonstrated high overall response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 after a median follow-up of 45 months.

Released: June 17, 2022

The chemotherapy-free combination of ponatinib and blinatumomab has demonstrated high response rates, including deep and durable responses, in patients with newly diagnosed and relapsed/refractory Ph+ ALL.

Released: June 6, 2022

Among older adults newly diagnosed with Ph-negative B-cell ALL, mini-hyperCVD plus inotuzumab with or without blinatumomab was associated with a 5-year OS rate of 47%.

Released: June 8, 2022

In this single-arm study, magrolimab plus azacitidine had a tolerable safety profile and achieved a CR rate of 33% in the frontline treatment of patients with TP53-mutated AML not eligible for intensive induction therapy.

Released: June 10, 2022

This pivotal phase II trial of glofitamab in patients with heavily pretreated, refractory DLBCL demonstrated a CR rate of 39.4%, with similar CR rates with or without previous CAR T-cell therapy.

Released: June 5, 2022

With approximately 6 years of follow-up of ECHELON-1, addition of brentuximab vedotin to AVD significantly improved overall survival vs ABVD in patients with previously untreated advanced cHL.

Released: June 7, 2022

Results of the ROSEWOOD trial suggest a favorable risk–benefit ratio for zanubrutinib and obinutuzumab, as indicated by improved ORR, DoR, PFS, and OS compared with obinutuzumab alone and no unexpected safety signals.

Released: June 6, 2022

Preliminary data suggest that combined treatment with anti–PD-1 and anti–LAG-3 agents provides antitumor activity with a high response rate and durable responses in patients with R/R classical Hodgkin lymphoma naive to anti–PD-1 treatment.

Released: June 15, 2022

The 3-year update of the CAPTIVATE fixed-duration cohort continues to show deep and durable responses with first-line ibrutinib + venetoclax in CLL/SLL including in patients with high-risk features.

Released: June 10, 2022

In a phase I/II trial, zilovertamab plus ibrutinib was generally well tolerated with robust efficacy compared with historical data for ibrutinib alone in MCL or CLL.

Released: June 15, 2022

In this updated analysis of the patient cohort with newly diagnosed high-risk DLBCL, epcoritamab SC combined with R-CHOP had a manageable safety profile and yielded an ORR of 100% and a CMR of 77%.

Released: June 16, 2022

In this updated analysis of the cohort with relapsed/refractory follicular lymphoma enrolled on an ongoing phase I/II trial, epcoritamab in combination with rituximab and lenalidomide was associated with a manageable safety profile and an ORR of 100%.

Released: June 16, 2022

After a median follow-up of approximately 4 years, acalabrutinib maintained significantly improved PFS with no new safety concerns vs standard-of-care regimens in patients with relapsed/refractory CLL.

Released: June 9, 2022

After a median follow-up of approximately 5 years, acalabrutinib-based combination therapy and monotherapy maintained significantly improved PFS vs chemoimmunotherapy in patients with treatment-naive CLL with no new safety concerns.

Released: June 7, 2022

In this interim analysis, use of post-ASCT carfilzomib/lenalidomide/dexamethasone with an MRD-directed, risk-adapted approach was associated with an improvement in PFS vs standard lenalidomide maintenance.

Released: June 9, 2022

Updated results from this investigator-initiated study suggest that GC012F confers rapid, deep, durable responses among high-risk and heavily pretreated patients with relapsed/refractory multiple myeloma.

Released: June 9, 2022

Teclistamab was associated with a high response rate and durable responses in patients with highly refractory MM not previously treated with BCMA-targeted therapy.

Released: June 7, 2022

In the phase III DETERMINATION trial, addition of ASCT to VRd induction with ongoing lenalidomide maintenance resulted in prolonged median PFS—but not OS—in newly diagnosed multiple myeloma.

Released: June 10, 2022

The addition of ibrutinib to chemoimmunotherapy prolonged median PFS by 2.3 years in older, previously untreated patients with MCL.

Released: June 7, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings